Cyclophosphamide-evoked heart failure involves pronounced co-suppression of cytoplasmic thioredoxin reductase activity and non-protein free thiol level

European Journal of Heart Failure

Volumn 11, Issue 2, 2009, Pages 154-162

  Wang, Xufang ^a   Zhang, Jinsong ^a   Xu, Tongwen ^a  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

Cardiac toxicity; Cyclophosphamide; Non protein free thiol; Thioredoxin reductase

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BUTHIONINE SULFOXIMINE; CREATINE KINASE MB; CYCLOPHOSPHAMIDE; LACTATE DEHYDROGENASE; NONPROTEIN THIOL; THIOL DERIVATIVE; THIOREDOXIN REDUCTASE; UNCLASSIFIED DRUG; ALKYLATING AGENT; GLUTATHIONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER; CARDIOTOXICITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SAFETY; ENZYME INACTIVATION; HEART FAILURE; KIDNEY; LEWIS CARCINOMA; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; CYTOPLASM; DRUG ANTAGONISM; HEART MUSCLE; METABOLISM; MOUSE STRAIN; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BUTHIONINE SULFOXIMINE; CYCLOPHOSPHAMIDE; CYTOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTATHIONE; HEART FAILURE; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; MYOCARDIUM; SULFHYDRYL COMPOUNDS; THIOREDOXIN-DISULFIDE REDUCTASE;

EID: 64549094225     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfn012     Document Type: Article

References (39)

1. Colvin OM. An overview of cyclophosphamide development and clinical applications. Curr Pharm Des 1999;5:555-560.
2. Tyndall A, Matucci-Cerinic M. Haematopoietic stem cell transplantation for the treatment of systemic sclerosis and other autoimmune disorders. Expert Opin Biol Ther 2003;3:1041-1049.
3. Zver S, Zadnik V, Bunc M, Rogel P, Cernelc P, Kozelj M. Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing auto-logous hematopoietic stem cell transplantation. IntJ Hematol 2007;85:408-414.
4. Morandi P, Ruffini PA, Benvenuto GM, Raimondi R, Fosser V. Cardiac toxicity of high-dose chemotherapy. Bone Marrow Transplant 2005;35:323-334.
5. Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 1981;141: 758-763.
6. Nordberg J, Arnér ESJ. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic Biol Med 2001;31:1287-1312.
7. Arnér ESJ, Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. EurJ Biochem 2000;267:6102-6109.
8. Nguyena P, Awwada RT, Smarta DDK, Spitzb DR, Giusa D. Thioredoxin reductase as a novel molecular target for cancer therapy. Cancer Lett 2006;236: 164-174.
9. Urig S, Becker K. On the potential of thioredoxin reductase inhibitors for cancer therapy. Semin Cancer Biol 2006;16:452-465.
10. Witte AB, Anestål K,Jerremalm E, Ehrsson H, Arnér ESJ. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic Biol Med 2005;39:696-703.
11. Wang X, Zhang J, Xu T. Cyclophosphamide as a potent inhibitor of tumor thioredoxin reductase in vivo. Toxicol Appl Pharmacol 2007;218:88-95.
12. Zhang J, Ma K, Wang H. Cyclophosphamide suppresses thioredoxin reductase in bladder tissue and its adaptive response via inductions of thioredoxin reductase and glutathione peroxidase. Chem Biol Interact 2006;162:24-30.
13. Smith CV, Jones DP, Guenthner TM, Lash LH, Lauterburg BH. Compartmentation of glutathione: implications for the study of toxicity and disease. Toxicol Appl Phar-macol1996;140:1-12.
14. Wu HY, Kang YJ. Inhibition of buthionine sulfoximine-enhanced doxorubicin toxicity in metallothionein overexpressing transgenic mouse heart. J Pharmacol Exp Ther1998;287:515-520.
15. Friedman HS, Colvin OM, Asiaka K, Popp J, Bossen EH, Reimer KA, Powell JB, Hilton J, Gross SS, Levi R, Bigner DD, Griffith OW. Glutathione protects cardiac and skeletal muscle from cyclophosphamide induced damage. Cancer Res1990;50:2455-2462.
16. Ellman GL Tissue sulfhydryl groups. Arch Biochem Biophys 1959;82:70-77.
17. Holmgren A, Bjo?rnstedt M. Thioredoxin and thioredoxin reductase. Methods Enzymol 1995;252:199-208.
18. Zhang J, Lu H. Ifosfamide induces acute renal failure via inhibition of thioredoxin reductase activity. Free Radic Biol Med 2007, doi:10.1016/ j.freeradbiomed.2007.08.020.
19. Ganther H, Ip C. Thioredoxin reductase activity in rat liver is not affected by supranutritional levels of monomethylated selenium in vivo and is inhibited only by high levels of selenium in vitro.J Nutr 2001 ;131:301 -304.
20. Rotruck JT, Pope AL, Ganther HE, Swanson AB, Hafeman DG, Hoekstra WG. Selenium: biochemical role as a component of glutathione peroxidase. Science 1973;179:588-590.
21. Habig WH, Pabst MJ, Jakoby WB. Glutathione-S-transferases: the first enzymatic step in mercapturic acid formation. J Biol Chem 1974;249:7130-7139.
22. Claiborne A. Catalase activity. In: Greenwald RA, ed. CRC Handbook of Methods for Oxygen Radical Research. Boca Raton: CRC Press; 1985. p283-284.
23. Sun Y, Larry W, Oberley W, Ying L A simple method for clinical assay of super-oxide dismutase. Clin Chem 1988;34:497-500.
24. Jakupoglu C, Przemeck GK, Schneider M, Moreno SG, Mayr N, Hatzopoulos AK, de Angelis MH, Wurst W, Bornkamm GW, Brielmeier M, Conrad M. Cytoplasmic thioredoxin reductase is essential for embryogenesis but dispensable for cardiac development. Mol Cell Biol 2005;25:1980-1988.
25. Han H, Bearss DJ, Browne LW, Calaluce R, Nagle RB, Von Hoff DD. Identification of differentially expressed genes in pancreatic cancer cells using cDNA micro-array. Cancer Res 2002;62:2890-2896.
26. Lincoln DT, Ali Emadi EM, Tonissen KF, Clarke FM. The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Anticancer Res 2003;23: 2425-2433.
27. Schuhmacher M, Kohlhuber F, Hölzel M, Kaiser C, Burtscher H, Jarsch M, Bornkamm GW, Laux G, Polack A, Weidle UH, Eick D. The transcriptional program of a human B cell line in response to Myc. Nucleic Acids Res 2001 ;29: 397-406.
28. Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC. Cardiotoxicity of cancer therapy. J Clin Oncol 2005;23:7685-7696.
29. Yamamoto M, Yang G, Hong C, Liu J, Holle E, Yu X, Wagner T, Vatner SF, Sadoshima J. Inhibition of endogenous thioredoxin in the heart increases oxidative stress and cardiac hypertrophy. J Clin Invest 2003;112:1395-1406.
30. Yamawaki H, Haendeler J, Berk BC. Thioredoxin: a key regulator of cardiovascular homeostasis. Cire Res 2003;93:1029-1033.
31. Venardos K, Harrison G, HeadrickJ, Perkins A. Auranofin increases apoptosis and ischaemia-reperfusion injury in the rat isolated heart, Clin Exp Pharmacol Physiol 2004;31:289-294.
32. Arnér ESJ, Björnstedt M, Holmgren A. 1-Chloro-2,4- dinitrobenzene is an irreversible inhibitor of human thioredoxin reductase. Loss of thioredoxin disulfide reductase activity is accompanied by a large increase in NADPH oxidase activity. J Biol Chem 1995;270:3479-3482.
33. Fang JG, Lu J, Holmgren A. Thioredoxin reductase is irreversibly modified by curcumin - a novel molecular mechanism for its anticancer activity. J Biol Chem 2005;280:25284-25290.
34. Anestål K, Arnér ESJ. Rapid induction of cell death by selenium-compromised thioredoxin reductase 1 but not by the fully active enzyme containing selenocys-teine.J Biol Chem 2003;278:15966-15972.
35. Arnér ESJ. Selenium compromised thioredoxin reductase-derived apoptotic proteins (SecTRAPs): potent killers of cancer cells: meeting abstract. Free Radic Res 2006;40:S51.
36. Lu J, Chew EH, Holmgren A. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci USA 2007;104:12288-12293.
37. Sakurai A, Nishimoto M, Himeno S, Imura N, Tsujimoto M, Kunimoto M, Hara S. Transcriptional regulation of thioredoxin reductase 1 expression by cadmium in vascular endothelial cells: role of NF-E2-related factor-2. J Cell Physiol 2005;203: 529-537.
38. Chen ZH, Saito Y, Yoshida Y, Sekine A, Noguchi N, Niki E. 4- Hydroxynonenal induces adaptive response and enhances PC12 cell tolerance primarily through induction of thioredoxin reductase 1 via activation of Nrf2. J Biol Chem 2005; 280:41921-41927.
39. Conrad M, Jakupoglu C, Moreno SG, Lippl S, Banjac A, Schneider M, Beck H, Hatzopoulos AK, Just U, Sinowatz F, Schmahl W, Chien KR, Wurst W, Bornkamm GW, Brielmeier M. Essential role for mitochondrial thioredoxin reductase in hematopoiesis, heart development, and heart function. Mol Cell Biol 2004;24:9414-9423.